Do we need adjuvant treatment after surgical resection of colorectal metastases?

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

Do we need adjuvant treatment after surgical resection of colorectal metastases?

Assoc. Prof. Joleen Hubbard, Assoc. Prof. Gerald Prager, Dr Dominik Modest

This month Ass. Prof. Joleen Hubbard, Dr Dominik Modest and Dr Gerald Prager debate the question ‘Do we need adjuvant treatment after surgical resection of colorectal metastases?’

Assoc. Prof. Joleen Hubbard

Medical Oncologist

Allina Health Cancer Institute

United States (US)

Assoc. Prof. Gerald Prager

Medical Oncologist

Medical University of Vienna

Austria

Dr Dominik Modest

Medical Oncologist

Charité Universitaetsmedizin

Germany

Biography Disclosures

Assoc. Prof. Joleen Hubbard

Medical Oncologist

Allina Health Cancer Institute

United States (US)

Dr Joleen Hubbard is Deputy Director of Clinical Research and Academic Affairs for the Allina Health Cancer Institute in Minneapolis, Minnesota. She was previously Assistant Professor of Medical Oncology at Mayo Clinic. She completed medical school and residency at the University of Minnesota and haematology/oncology training at Mayo Clinic, Rochester, Minnesota. Dr Hubbard specialises in the treatment of gastrointestinal cancers, focusing on colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials, investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty. She serves as a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network.

Assoc. Prof. Joleen Hubbard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory boards: Bayer, Merck, BeiGene, Incyte

Research funding to institution: Merck, Boston Biomedical, Treos Bio, Senhwa Pharmaceuticals, Bayer, Incyte, TriOncology, Seattle Genetics, Hutchison MediPharma, Pionyr Immunotherapeutics, Trovogene, G1 Therapeutics, Roche

Biography Disclosures

Assoc. Prof. Gerald Prager

Medical Oncologist

Medical University of Vienna

Austria

Dr Gerald Prager is an Associate Professor of Medicine, Board Certified for Internal Medicine Board and Certified for Haematology and Medical Oncology. In 2009, he received his M.D. from the University of Vienna. Currently, Dr Prager is Director of the Colorectal Cancer Unit of the Department of Medical Oncology at the Medical University of Vienna. He is also a member of the ESMO 2014 Scientific Committee. The research interest of his lab focuses on (tumour-) angiogenesis via regulation of endothelial cell survival and migration by cell / extracellular-matrix interaction. Through his clinical training in haemato-oncology, he became a member of the sought-after group of medical researches. He achieved his expertise in international renowned labs at University of California, San Diego, the Norris Cancer Center, Los Angeles and the Department of Vascular Biology, Mississippi University for Women (MUW). His work is honoured by 19 international awards and resulted in publications in international highly renowned journals. Dr Prager’s young research group is embedded in an international cancer research campus associated with Medical University of Vienna (MUV).

Assoc. Prof. Gerald Prager has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Bayer, BMS, Incyte, Merck Serono, MSD, Servier, Takeda

Biography Disclosures

Dr Dominik Modest

Medical Oncologist

Charité Universitaetsmedizin

Germany

Prof. Dr Dominik Modest studied medicine at the Charité in Berlin, Germany and at the University of Bern, Switzerland. Currently, after 10 years at the LMU in Munich, Germany, he is a physician at the Charité Universitaetsmedizin Berlin, Germany. His research activities focus on metastatic colorectal cancer and include the concept and coordination of trials for the FIRE study group and the Arbeitsgemeinschaft Internistische Onkologie (AIO). Prof. Dr Modest also coordinates the translational research components of these trials, aiming to identify prognostic and predictive biomarkers of metastatic colorectal cancer. His research has been published in several papers in scientific journals. In 2015, he received a postdoctoral qualification on factors for personalisation of metastatic colorectal cancer therapy and a full professorship in 2020. Prof. Dr Modest is an active member of several national and international cancer associations and served as spokesman for the Young Medical Oncologists of the AIO until 2014.

Dr Dominik Modest has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Merck, Servier, Pierre Fabre, Sanofi, Lilly, Onkowissen, AstraZeneca, MSD, BMS, Seagen and GSK

time | open 5 min | Sep 2021

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download the slides

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest

Prof. Dimitrios Tsakiris

Dr Lars Asmis

Podcast

2 min

Cancer and Thrombosis

Sep 2023

Dr Elisa Agostinetto

Prof. Valentina Guarneri

Interactive patient case

15 min

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Meta...

Sep 2023

Prof. Chee-Kiat Tan

Publication

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.